Psoriatic arthritis
 
  Richard Conway RichardPAConway
            3 years 11 months ago 
          
         
          Dr Exarchou presents incidence of PsA in Sweden. 22/100000. 75% received DMARDs within 2 years, which seems high, so perhaps this is tip of iceberg with milder cases undiagnosed. Abstr#0571 #ACR21 @RheumNow https://t.co/kANG6KBnOd
        
         
 
  swethaann23 swethaann23
            3 years 11 months ago 
          
         
          Novel study exploring microbial differences in MZ twins discordant for psoriatic disease
⭐️Ruminococcus 🔽/❎ Gut of Ps pts and maybe associated with Ps Dis
⭐️NL skin scalp of Psoriatic pts 🔽 microbial diversity compared to unaffected twins
Abst#0944 #ACR21 #ACRBest @RheumNow
        
         
  Richard Conway RichardPAConway
            3 years 11 months ago 
          
         
          Dr Manasson presents on microbiome differences between monozygotic twins discordant for psoriatic disease. Differences seen in gut (Ruminococcus virtually absent in psoriatic) and scalp non-lesional skin microbiomes Abstr#0944 #ACR21 @RheumNow https://t.co/8Ch0M4dwUH
        
         
 
  Eric Dein ericdeinmd
            3 years 11 months ago 
          
         
          #ACR21 Abst#0786. Fibroscan screening for liver injury in pts on MTX:
▶️No significant correlation between cumulative MTX dose and liver stiffness by fibroscan, even at high dose MTX.
⭐️Age, sex, waist circumference, BMI are risks
@Rheumnow https://t.co/IhcNr9fhEh https://t.co/c7TUoGrNZ7
        
        
       
 
  Meral K. El Ramahi, MD MeralElRamahiMD
            3 years 11 months ago 
          
         
          #ACR21 Abst#0449:
Ever wish you had a tool to help you predict which PsA pts will progress to radiographic damage?
➡️Proteomic approaches identified 103 candidate biomarker peptides related to 69 proteins that can potentially do so!
@Rheumnow @uptoTate 
https://t.co/uUsZlBLTWC
        
        
       
  Meral K. El Ramahi, MD MeralElRamahiMD
            3 years 11 months ago 
          
         
          #ACR21 Abst#0452
⭐️Total Body PET/CT (TB-PET/CT) as a tool to identify subclinical PsA at the point of transition from psoriasis (PsO). 
➡️Should all pts w/ new dx of PsO have a baseline TB-PET/CT to identify early PsA?
#ACRBest @Rheumnow @uptoTate 
https://t.co/IuxVuJgFSd https://t.co/AIuH9CIucy
        
        
       
 
  Meral K. El Ramahi, MD MeralElRamahiMD
            3 years 11 months ago 
          
         
          #ACR21 Abst#0182
Does tenderness in non-swollen joints of PsA or RA pts portend inflammation & radiographic damage? 
⭐️NO, except in early PsA! 
➡️Abnormal PDUS associated w/ radiographic progression vs tenderness otherwise
#ACRBest @Rheumnow @uptoTate
https://t.co/iB1E0SL45e https://t.co/3Q30LeCMH4
        
        
       
 
  TheDaoIndex KDAO2011
            3 years 11 months ago 
          
         
          @JointMD shares his thoughts on IL23, IL17, TNF inh- where/when/how we might use them. @RheumNow #acr21 https://t.co/mVw05iFPhF
        
        
      
        
      The arsenal of therapeutics for psoriatic arthritis continues to increase. Risankizumab is an IL-23 inhibitor to the p19 subunit, currently being investigated for treatment of psoriatic arthritis.
    
  
        
      The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).
The Year in Review featured a clinical vs basic science Brigham and Women’s Hospital faceoff between its two faculty, Dr. Karen Costenbader and Dr. Michael Brenner.
    
   
  TheDaoIndex KDAO2011
            3 years 11 months ago 
          
         
          👉Get contrast if ordering an MRI to eval for inflamm. arthritis
👉Heel spur vs. enthesitis?  Look for erosions at dorsum of calcaneus & other signs of inflamm 
👉DISH vs. axial PsA? DISH➡️contiguous bony ossific'n up anterior margin of the vertebral bodies; PsA not cont.
        
         
  TheDaoIndex KDAO2011
            3 years 11 months ago 
          
         
          KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA:
👉some benefits of risankizumab for axial disease
👉no data regarding bowel disease
👉pts did remain on background DMARDS, steroids.
(2/2)
        
         
  

 
 
 
 
 
 
 
 
          
           
          
           
          
           
 
 
 
 
 
 Poster Hall
Poster Hall